1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fostair (Asthma) - Forecast and Market Analysis to 2023

Fostair (Asthma) - Forecast and Market Analysis to 2023

  • August 2014
  • -
  • Global Data
  • -
  • 53 pages

Fostair (Asthma) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Fostair (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Fostair, developed by Chiesi, is an FDC of the ICS beclomethasone dipropionate and the LABA formoterol fumarate. Beclomethasone dipropionate is a prodrug that is metabolized to two active metabolites. The 17-monopropionate metabolite has a 30-fold greater affinity for glucocorticoid receptors than its 21-monopropionate counterpart and inhibits the secretion of mediators involved in asthma. Beclomethasone dipropionate is marketed as a standalone product, Teva’s QVAR. Formoterol fumarate is a highly selective LABA. It acts by increasing cAMP, which, in turn, leads to relaxation of the bronchial smooth muscle. This way, formoterol inhibits the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from the human lung. AstraZeneca markets formoterol as a standalone drug under the name of Oxis Turbuhaler. Other companies also market formoterol, one example being Novartis’ Foradil.

Scope

- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fostair including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fostair for the top five countries from 2013 to 2023.
- Sales information covered for France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fostair performance
- Obtain sales forecast for Fostair from 2013-2023 in top five countries (France, Germany, Italy, Spain and the UK)

Table Of Contents

Fostair (Asthma) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Prognosis 15
3.1.4 Quality of Life 15
3.2 Symptoms 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 20
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 27
6 Fostair (beclomethasone dipropionate/formoterol fumarate) 31
6.1 Overview 31
6.2 Efficacy 32
6.3 Safety 33
6.4 SWOT Analysis 34
6.5 Forecast 34
7 Appendix 36
7.1 Bibliography 36
7.2 Abbreviations 40
7.3 Methodology 43
7.4 Forecasting Methodology 43
7.4.1 Diagnosed Asthma Patients 43
7.4.2 Percent Drug-Treated Patients 44
7.4.3 General Pricing Assumptions 44
7.4.4 Individual Drug Assumptions 45
7.4.5 Generic Erosion 45
7.5 Physicians and Specialists Included in This Study 46
7.6 About the Authors 49
7.6.1 Author 49
7.6.2 Author/Reviewer 49
7.6.3 Reviewer 50
7.6.4 Global Head of Healthcare 51
7.7 About GlobalData 52
7.8 Disclaimer 52

1.1 List of Tables

Table 1: Symptoms of Asthma 16
Table 2: Treatment Guidelines for Asthma by Country 18
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013 19
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency 22
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age 24
Table 6: Leading Treatments for Asthma, 2014 30
Table 7: Product Profile - Fostair 32
Table 8: Efficacy - Fostair Versus Symbicort 33
Table 9: Safety - Fostair Versus Symbicort 33
Table 10: Fostair SWOT Analysis, 2014 34
Table 11: Global Sales Forecast ($) for Fostair, 2013-2023 35
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 48

1.2 List of Figures

Figure 1:Stepwise Disease Management Approach for Asthma in Adults 21
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Biguanide Market

  • January 2017
    8 pages
  • Biguanide  

    Genetic  

    Chromosome  

View report >

Therapy Market in the US

  • January 2017
    13 pages
  • Therapy  

  • United States  

View report >

Biological Therapy Industry in the US

  • January 2017
    9 pages
  • Vaccine  

  • United States  

View report >

Related Market Segments :

Therapy
Respiratory Treatment
Asthma

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.